Alnylam Pharmaceuticals ALNY Total Liabilities
Total Liabilities at other companies
Other financials
Where this comes from
Reported directly by Alnylam Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:Liabilities.
The official record: Alnylam Pharmaceuticals’s 10-Q, filed July 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Alnylam Pharmaceuticals's total liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Alnylam Pharmaceuticals's total liabilities?
- Alnylam Pharmaceuticals (ALNY) reported total liabilities of $4.2B in Q2 2026.
- How has Alnylam Pharmaceuticals's total liabilities changed year-over-year?
- Alnylam Pharmaceuticals's total liabilities decreased by 2.6% year-over-year, from $4.32B to $4.2B.
- What is the long-term trend for Alnylam Pharmaceuticals's total liabilities?
- Over 5 years (2020 to 2025), Alnylam Pharmaceuticals's total liabilities has grown at a 11.8% compound annual growth rate (CAGR), from $2.39B to $4.18B.
- What does total liabilities mean?
- The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.